JP2019515666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515666A5 JP2019515666A5 JP2018552794A JP2018552794A JP2019515666A5 JP 2019515666 A5 JP2019515666 A5 JP 2019515666A5 JP 2018552794 A JP2018552794 A JP 2018552794A JP 2018552794 A JP2018552794 A JP 2018552794A JP 2019515666 A5 JP2019515666 A5 JP 2019515666A5
- Authority
- JP
- Japan
- Prior art keywords
- rrs
- vector
- nucleotide sequence
- sequence encoding
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 226
- 239000002773 nucleotide Substances 0.000 claims description 123
- 125000003729 nucleotide group Chemical group 0.000 claims description 123
- 108020004707 nucleic acids Proteins 0.000 claims description 85
- 102000039446 nucleic acids Human genes 0.000 claims description 85
- 150000007523 nucleic acids Chemical class 0.000 claims description 85
- 210000004027 cell Anatomy 0.000 claims description 71
- 102100030355 Host cell factor 1 Human genes 0.000 claims description 62
- 239000003550 marker Substances 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 102000025171 antigen binding proteins Human genes 0.000 claims description 29
- 108091000831 antigen binding proteins Proteins 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 208000005229 Autosomal recessive Robinow syndrome Diseases 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 238000001945 resonance Rayleigh scattering spectroscopy Methods 0.000 claims description 16
- 102000018120 Recombinases Human genes 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000010354 integration Effects 0.000 description 2
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114374A JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2025170326A JP2025188169A (ja) | 2016-04-20 | 2025-10-08 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 | |
| US62/325,400 | 2016-04-20 | ||
| PCT/US2017/028555 WO2017184832A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114374A Division JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515666A JP2019515666A (ja) | 2019-06-13 |
| JP2019515666A5 true JP2019515666A5 (enExample) | 2020-05-28 |
| JP7096770B2 JP7096770B2 (ja) | 2022-07-06 |
Family
ID=58701851
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552794A Active JP7096770B2 (ja) | 2016-04-20 | 2017-04-20 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2021114374A Pending JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A Active JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2025170326A Pending JP2025188169A (ja) | 2016-04-20 | 2025-10-08 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114374A Pending JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A Active JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2025170326A Pending JP2025188169A (ja) | 2016-04-20 | 2025-10-08 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (enExample) |
| EP (1) | EP3445781A1 (enExample) |
| JP (4) | JP7096770B2 (enExample) |
| KR (3) | KR102906454B1 (enExample) |
| CN (2) | CN109195986B (enExample) |
| AR (1) | AR109451A1 (enExample) |
| AU (2) | AU2017253241B2 (enExample) |
| BR (1) | BR112018071283A2 (enExample) |
| CA (1) | CA3015389A1 (enExample) |
| EA (1) | EA201892010A1 (enExample) |
| IL (2) | IL262266B2 (enExample) |
| MX (2) | MX2018012868A (enExample) |
| SG (2) | SG10202010155YA (enExample) |
| TW (2) | TW202415767A (enExample) |
| WO (1) | WO2017184832A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012868A (es) | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| CN113631711B (zh) * | 2018-12-21 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| EP3950938A4 (en) * | 2019-04-02 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN |
| AU2020308002A1 (en) * | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| US20230304062A1 (en) | 2021-10-18 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Controlled transcription of polynucleotides |
| US12234472B2 (en) | 2021-10-18 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| TW202334402A (zh) | 2021-10-18 | 2023-09-01 | 美商再生元醫藥公司 | 包含整合ｃａｓ９基因以產生穩定整合位點的哺乳動物細胞，以及包含穩定整合位點及其他位點的哺乳動物細胞 |
| EP4453227A1 (en) * | 2021-12-22 | 2024-10-30 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| US20250361524A1 (en) * | 2022-06-10 | 2025-11-27 | Fujifilm Diosynth Biotechnologies Uk Limited | Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool |
| CN121794393A (zh) | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2026050618A1 (en) | 2024-08-29 | 2026-03-05 | Regeneron Pharmaceuticals, Inc. | Polynucleotide constructs and cell lines for recombinant aav production |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| AU2003237259B2 (en) | 2002-05-29 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| CA2504595A1 (en) | 2002-11-14 | 2004-06-03 | Lynne Krummen | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| WO2008151219A1 (en) * | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8409838B2 (en) * | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| CN102575264A (zh) | 2009-09-18 | 2012-07-11 | 瑟莱克斯公司 | 增加的转基因表达和加工的产品和方法 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN104011080B (zh) | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TW202423993A (zh) | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2017005306A (es) * | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
| KR102777500B1 (ko) | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| MX2018012868A (es) * | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
-
2017
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en not_active Ceased
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 IL IL262266A patent/IL262266B2/en unknown
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt active Search and Examination
- 2017-04-20 KR KR1020237020953A patent/KR102906454B1/ko active Active
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active Active
- 2017-04-20 KR KR1020257043281A patent/KR20260011194A/ko active Pending
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
-
2018
- 2018-10-19 MX MX2025003852A patent/MX2025003852A/es unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US12528883B2/en active Active
-
2023
- 2023-11-29 JP JP2023201924A patent/JP7781128B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
-
2025
- 2025-10-08 JP JP2025170326A patent/JP2025188169A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514358A5 (enExample) | ||
| JP2021087433A5 (enExample) | ||
| JP2006515520A5 (enExample) | ||
| ES2909150T3 (es) | Composiciones y colecciones que comprenden receptores de células T recombinantes y procedimientos de uso de receptores de células t recombinantes | |
| JP2019150066A5 (enExample) | ||
| JP2020503885A5 (enExample) | ||
| SA519401562B1 (ar) | بروتينات دمج FC دايمرية غير متجانسة لـ IL15/IL15Rα | |
| JP2020501516A5 (enExample) | ||
| JP2021534770A5 (enExample) | ||
| JP2018533963A5 (enExample) | ||
| RU2011129459A (ru) | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение | |
| RU2014118869A (ru) | Мыши с ограниченной тяжелой цепью иммуноглобулина | |
| JP2018525007A (ja) | 免疫グロブリンの産生増強 | |
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| JP2015519055A5 (enExample) | ||
| EP2502934A1 (en) | Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds | |
| JP2011504721A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2013532974A5 (enExample) | ||
| AU2018208191A1 (en) | Anti-GPC3 antibody | |
| RU2018129169A (ru) | Грызуны, имеющие сконструированный участок разнообразия тяжелой цепи | |
| KR20250021382A (ko) | 바이러스 펩티드 및 이의 용도 | |
| JP2017525368A5 (enExample) | ||
| WO2023247779A1 (en) | Animal models and therapeutic molecules | |
| RU2020112751A (ru) | Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q |